You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,004,812


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,004,812
Title:Antibody-drug conjugates and immunotoxins
Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.
Inventor(s): Kontermann; Roland (Nurtingen, DE), Pfizenmaier; Klaus (Tiefenbronn, DE), Ferrer; Cristina (Madrid, ES), Fabre; Myriam (Barcelona, ES), Simon; Laureano (Derio, ES)
Assignee: Oncomatryx Biopharma, S.L. (Derio, ES)
Application Number:15/116,419
Patent Claims:1. A conjugate having the formula I: A-(L-D).sub.p (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin; and p is 1 to 10, wherein the cytolysin is of formula IV: ##STR00035## wherein: R.sup.2 is H or C.sub.1-C.sub.4 alkyl; R.sup.6 is C.sub.1-C.sub.6 alkyl; R.sup.7 is C.sub.1-C.sub.6 alkyl, CH.sub.2OR.sup.19 or CH.sub.2OCOR.sup.20, wherein R.sup.19 is alkyl, R.sup.20 is C.sub.2-C.sub.6-alkenyl, phenyl, or CH.sub.2-phenyl; R.sup.9 is C.sub.1-C.sub.6 alkyl; R.sup.10 is H, OH, O-alkyl or O-acetyl; f is 1 or 2; R.sup.11 has the following structure: ##STR00036## wherein R.sup.21 is H, OH, halogen, NH.sub.2, alkyloxy, phenyl, alkyl amino or dialkyl amino; R.sup.16 is H or a C.sub.1-C.sub.6-alkyl group; R.sup.17 is directly or indirectly attached to linker L; and q is 0, 1, 2 or 3.

2. The conjugate of claim 1, wherein A comprises heavy chain complementarity determining regions 1-3 (CDRH1-3) and light chain complementarity determining regions 1-3 (CDRL1-3) having the following amino acid sequences: (i) CDRH1: SEQ ID NO: 7; (ii) CDRH2: SEQ ID NO: 8; (iii) CDRH3: SEQ ID NO: 9; (iv) CDRL1: SEQ ID NO: 10; (v) CDRL2: SEQ ID NO: 11; and (vi) CDRL3: SEQ ID NO: 12.

3. The conjugate of claim 2, wherein A comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 6.

4. The conjugate of claim 2, wherein A comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.

5. The conjugate of claim 1, wherein R.sup.17 is C(O)X, CONHNHX, OX, NHX or SX, wherein X is a bond to linker L.

6. The conjugate of claim 1, wherein linker L further comprises a spacer.

7. The conjugate of claim 6, wherein the spacer has a chain length of 2 to 30 atoms.

8. The conjugate of claim 7, wherein the spacer comprises or consists of a group --(CH.sub.2).sub.n-- or --(OCH.sub.2CH.sub.2).sub.n--, wherein n=1 to 10.

9. The conjugate of claim 6, wherein the spacer is directly attached to group R.sup.17, or is attached to group R.sup.17 via a bridging group.

10. The conjugate of claim 9, wherein the spacer is attached to group R.sup.17 via a --C(O)X bridging group, wherein X is a bond to R.sup.17.

11. The conjugate of claim 1, wherein D comprises a cytolysin having the following structure: ##STR00037## or ##STR00038##

12. The conjugate of claim 1, wherein L comprises an attachment group for attachment to A and protease cleavable portion.

13. The conjugate of claim 12, wherein L comprises maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate.

14. The conjugate of claim 1, wherein L-D has a structure selected from the group consisting of: ##STR00039##

15. A method of treating a tumor in a mammalian subject, wherein said tumor and/or stroma surrounding said tumor expresses endoglin, said method comprising administering a therapeutically effective amount of a conjugate as defined in claim 1 to the subject in need thereof.

16. The method of claim 15, wherein said conjugate is administered simultaneously, sequentially or separately with one or more other antitumor drugs.

17. The method of claim 16, wherein said one or more other antitumor drugs comprise a cytotoxic chemotherapeutic agent or an anti-angiogenic agent or an immunotherapeutic agent.

18. The method of claim 17, wherein said one or more other antitumor drugs comprise Gemcitabine, Abraxane, bevacizumab, itraconazole, or carboxyamidotriazole, an anti-PD-1 molecule or an anti-PD-L1 molecule.

19. The method of claim 18, wherein said anti-PD-1 molecule or anti-PD-L1 molecule comprises nivolumab or pembrolizumab.

20. The method of claim 15, wherein the tumor is an endoglin-expressing blood neoplasm, pancreatic cancer, Ewing sarcoma, breast cancer, melanoma, lung cancer, head and neck cancer, ovarian cancer, bladder cancer or colon cancer.

21. A method of treating an endoglin-expressing inflammatory condition or an endoglin-expressing eye disease in a mammalian subject, said method comprising administering a therapeutically effective amount of the conjugate as defined in claim 1 to the subject in need thereof.

22. The method according to claim 21, wherein: said inflammatory condition is endoglin-expressing rheumatoid arthritis; and/or said eye disease is endoglin-expressing diabetic retinopathy or endoglin-expressing macular degeneration.

Details for Patent 10,004,812

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,004,812 2034-02-06
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 10,004,812 2034-02-06
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 10,004,812 2034-02-06
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 December 22, 2014 10,004,812 2034-02-06
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 October 04, 2017 10,004,812 2034-02-06
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 August 27, 2021 10,004,812 2034-02-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.